In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Joint Registries and Trials

The European Heart Rhythm Association (EHRA) is organising, and in some cases supporting surveys


European Lead Extraction ConTRolled Registry - ELECTRa Registry.

European Lead Extraction Controlled Registry (ELECTRa) is the first large, prospective, multi-centre, European-controlled
registry of consecutive patients undergoing Transvenous Lead Extraction (TLE) procedures.  Recruitment of patients began in November2012 and ended in May 2014 with a follow-up phase at one year. Preliminary results on TLE in Europe was presented during the 2014 ESC Congress in Barcelona, the EHRA EUROPACE - CARDIOSTIM 2015 meeting in Milan, and at the 2015 ESC Congress in London.. More details here.

Early Comprehensive Atrial Fibrillation Stroke Prevention Trial (EAST)

Early Comprehensive Atrial Fibrillation Stroke Prevention Trial (EAST) is a European, investigator-initiated study jointly conducted by AFNET and EHRA.  The trial is supported by a unique partnership including Sanofi Aventis and St Jude Medical, receiving further funding from the German Ministry of Education and Research (BMBF) through the German Centre for Heart Research (DZHK).

Its aims are to determine whether early, standardised, rhythm control intervention can help prevent adverse cardiovascular outcomes associated with atrial fibrillation, including stroke and death.  At the end of 2015, over 2 350 patients were enrolled in 11 European countries. We expect to continue enrolment until early 2016.

For more information please contact : 

European Cardiac Resynchronisation Therapy Survey

The primary objective of this survey is to describe current European practice based on a representative sampling in 13 countries. More details here